NetworkNewsBreaks Genprex, Inc. (NASDAQ: GNPX) Joins Russell 3000(R) Index
Jun 29, 2020 (MENAFN via COMTEX) —
(MENAFN – Investor Brand Network) Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced that it was added to the Russell 3000(R) Index after the market closed on Friday, June 26, 2020 as part of the 2020 Russell U.S. Indexes reconstitution. ‘Genprex is excited to be a member of the Russell 3000 Index, and we look forward to sharing our story and unique approaches for the treatment of lung cancer and diabetes with a wider group of investors,’ Rodney Varner, chairman and CEO of Genprex, stated in the news release. ‘We believe the Company’s future is bright as we work to secure better outcomes for patients suffering from these serious medical conditions.’
To view the full press release, visit http://nnw.fm/e9fTg
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to in-license and develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company’s lead product candidate, Oncoprex(TM), is being evaluated as a treatment for non-small cell lung cancer (‘NSCLC’). Oncoprex has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. In January